Text Size

Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

This study is not yet open for participant recruitment.
Verified June 2012 by Rabin Medical Center
Sponsor:
Information provided by (Responsible Party):
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT01709461
First received: October 14, 2012
Last updated: October 16, 2012
Last verified: June 2012
History of Changes
  Purpose

the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.


Condition
Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Rabin Medical Center:

Estimated Enrollment: 12
Study Start Date: October 2012
  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving Rasgiline Mesylate.

Criteria

Inclusion Criteria:

  • subjects who are willing to contiue this treatment.
  • subjects who took part in the TVP 1012/501 clinical trail.

Exclusion Criteria:

  • subjects who didn't take part in the TVP 1012/501 clinical trail.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01709461

Contacts
Contact: Ruth Djaldetti, Professor 972-9378218/9 ruthdjal@clalit.org.il
Contact: Yaniv roditi, Msc 972-39236843 yar@clalit.org.il

Locations
Israel
Rabin Medical Center Beilinson Campus Not yet recruiting
Petach Tiqva, Hamerkaz, Israel, 49100
Principal Investigator: Ruth Djaldetti, Professor            
Sponsors and Collaborators
Rabin Medical Center
  More Information

No publications provided

Responsible Party: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT01709461     History of Changes
Other Study ID Numbers: RD 06 - 12
Study First Received: October 14, 2012
Last Updated: October 16, 2012
Health Authority: Israeli: Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
 Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 16, 2013